Northside Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Northside Hospital sits in the top decile of US sponsors by registered trial count (#604 of 15,742 sponsors by registered trial count).
Northside Hospital: 26 sponsored US clinical trials, 7 recruiting.
Northside Hospital sponsors 26 registered US clinical trials on ClinicalTrials.gov, 7 of them currently recruiting, and 12 completed. 0 of these trials are in Phase 3-4 (later-stage) and 22 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Myeloma, with 2 trials.
Top-decile sponsor footprint
Northside Hospital ranks in the top decile of sponsors by registered trial count (#604 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
12 of 17 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (70.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
26 total, page 1 of 1
Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide
NCT06828796
CAR T-cell Therapy in Patients With Renal Dysfunction
NCT05909059
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
NCT06046248
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
NCT05519579
Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation
NCT05417971
GM-CSF With Post-Transplant Cyclophosphamide
NCT04237623
Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia
NCT02828592
Axatilimab + CAR-T for High-Risk Lymphoma
NCT07638982
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
NCT07511062
Use of Convalescent Plasma for COVID-19
NCT04408040
Ibrutinib and Rituxan for Chronic GVHD
NCT04235036
Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant
NCT02771197
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
NCT02581007
High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma
NCT02416206
Nonmyeloablative Haploidentical Transplant Followed by MLN9708
NCT02169791
MOSTEGRA TRIAL:MO-(Dified) STE-(nt) GRA(-ft): Surgeon-modified Fenestrated-branched Stent-grafts
NCT02101463
Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients
NCT01370408
Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases
NCT01336712
Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)
NCT01161628
FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates
NCT01328873
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant
NCT01244906
Caregiver Burden and Distress in Hematopoeitic Stem Cell Transplant
NCT01084694
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer
NCT00782379
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
NCT00787761
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
NCT00827099
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
NCT00818961
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 20 |
What is open in the Northside Hospital pipeline
7 recruiting of 26 indexed (27% open); 12 completed (46%).
Phase mix: 0 late (III/IV) vs 22 early (I/II) (early-phase heavy).
Top condition: Multiple Myeloma (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Northside Hospital: open-pipeline peers nationwide
Peers matched on 26 registered trials and 27% open enrollment, not the therapeutic-area sidebar.
Northside Hospital sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 26 trials (± recruiting share)
- Abbott Diabetes Care · 26 trials · 12% recruiting
- Aldeyra Therapeutics · 26 trials · 4% recruiting
- California Polytechnic State University-San Luis Obispo · 26 trials · 19% recruiting
- DexCom · 26 trials · 4% recruiting
Sponsors near 27% open enrollment (± trial volume)
- Walter Reed National Military Medical Center · 27% recruiting · 48 trials
- University of Illinois at Chicago · 27% recruiting · 430 trials
- San Diego State University · 27% recruiting · 118 trials
- Coherus Oncology · 27% recruiting · 15 trials
Related
What to do with this Northside Hospital page
26 registered trials is a research-attention snapshot, not an endorsement of Northside Hospital or any single study.
- 7 of Northside Hospital's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Multiple Myeloma is the condition Northside Hospital studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Myeloma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Northside Hospital pipeline card: 26 registered trials from official public datasets.Report a data error.